Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:


Less-expensive diuretics found superior in treatment of hypertension


A major clinical trial of blood pressure medications has concluded that an inexpensive diuretic (water pill) is more effective in treating high blood pressure and preventing cardiovascular disease than newer more expensive medications.

The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), conducted from February 1994 though March 2002, compared the drugs for use in starting treatment for high blood pressure.

"The preferred drug is the diuretic for three reasons. It provides better control of hypertension; it reduces complications from hypertension--particularly heart failure-- more effectively; and it is 10 to 20 times less expensive than the other drugs used in the trial," said Curt Furberg, M.D., Ph.D., of Wake Forest University Baptist Medical Center, chairman of the study’s steering committee.

ALLHAT is the largest study ever to compare different types of hypertension drugs. It included more than 33,000 participants age 55 years or older at 623 clinical sites in North America. All the patients had hypertension and at least one other coronary heart disease risk factor. Approximately 50 percent of the participants were women and 35 percent were African-American.

"The bottom line is ALLHAT has shown that it matters which drug you use to control hypertension," said Furberg.

Participants were randomly assigned to receive the diuretic chlorthalidone, amlodipine (a calcium channel blocker sold under the name Norvasc) or lisinopril, (an angiotensin-converting enzyme (ACE) inhibitor sold under the names Prinivil and Zestril.)

In 2000, another drug used in the trial, doxazosin (an alpha-blocker sold under the name Cardura) was pulled from the trial because it was determined early in ALLHAT that it was not as effective as the less expensive diuretic medication.

The study does not recommend that patients stop taking their medication if they are using a drug other than a diuretic. However they are encouraged to speak with their physicians about adding or switching to a diuretic for their treatment.

ALLHAT’s findings indicate that most patients will need more than one drug to adequately control their blood pressure and one of the drugs should be a diuretic. The National Heart, Lung and Blood Institute, part of the National Institutes of Health, supported the study.

Contact: Jim Steele,, Jonnie Rohrer, ´, Karen Richardson, or Barbara Hahn,, 716-4587.

Jim Steele | EurekAlert!
Further information:

More articles from Health and Medicine:

nachricht NIH scientists describe potential antibody treatment for multidrug-resistant K. pneumoniae
14.03.2018 | NIH/National Institute of Allergy and Infectious Diseases

nachricht Researchers identify key step in viral replication
13.03.2018 | University of Pittsburgh Schools of the Health Sciences

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Locomotion control with photopigments

Researchers from Göttingen University discover additional function of opsins

Animal photoreceptors capture light with photopigments. Researchers from the University of Göttingen have now discovered that these photopigments fulfill an...

Im Focus: Surveying the Arctic: Tracking down carbon particles

Researchers embark on aerial campaign over Northeast Greenland

On 15 March, the AWI research aeroplane Polar 5 will depart for Greenland. Concentrating on the furthest northeast region of the island, an international team...

Im Focus: Unique Insights into the Antarctic Ice Shelf System

Data collected on ocean-ice interactions in the little-researched regions of the far south

The world’s second-largest ice shelf was the destination for a Polarstern expedition that ended in Punta Arenas, Chile on 14th March 2018. Oceanographers from...

Im Focus: ILA 2018: Laser alternative to hexavalent chromium coating

At the 2018 ILA Berlin Air Show from April 25–29, the Fraunhofer Institute for Laser Technology ILT is showcasing extreme high-speed Laser Material Deposition (EHLA): A video documents how for metal components that are highly loaded, EHLA has already proved itself as an alternative to hard chrome plating, which is now allowed only under special conditions.

When the EU restricted the use of hexavalent chromium compounds to special applications requiring authorization, the move prompted a rethink in the surface...

Im Focus: Radar for navigation support from autonomous flying drones

At the ILA Berlin, hall 4, booth 202, Fraunhofer FHR will present two radar sensors for navigation support of drones. The sensors are valuable components in the implementation of autonomous flying drones: they function as obstacle detectors to prevent collisions. Radar sensors also operate reliably in restricted visibility, e.g. in foggy or dusty conditions. Due to their ability to measure distances with high precision, the radar sensors can also be used as altimeters when other sources of information such as barometers or GPS are not available or cannot operate optimally.

Drones play an increasingly important role in the area of logistics and services. Well-known logistic companies place great hope in these compact, aerial...

All Focus news of the innovation-report >>>



Industry & Economy
Event News

Ultrafast Wireless and Chip Design at the DATE Conference in Dresden

16.03.2018 | Event News

International Tinnitus Conference of the Tinnitus Research Initiative in Regensburg

13.03.2018 | Event News

International Virtual Reality Conference “IEEE VR 2018” comes to Reutlingen, Germany

08.03.2018 | Event News

Latest News

Wandering greenhouse gas

16.03.2018 | Earth Sciences

'Frequency combs' ID chemicals within the mid-infrared spectral region

16.03.2018 | Physics and Astronomy

Biologists unravel another mystery of what makes DNA go 'loopy'

16.03.2018 | Life Sciences

Science & Research
Overview of more VideoLinks >>>